Welcome to the 2022 Targeted Therapies Forum’s breakout session, where renowned oncologist Dr. Dagogo-Jack delves into the nuances of BRAF and NTRK inhibitors and their pivotal role in early-stage NSCLC. Navigate the intricate pathways of these targeted treatments and understand their transformative potential in revolutionizing the landscape of non-small cell lung cancer (NSCLC) care. Heartfelt appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To stay updated on cutting-edge advancements in oncology, please visit http://cancerGRACE.org/. Engage, discuss, and share your insights with a community of experts at https://cancergrace.org/forum.
Author: Editor
Delving into the intricate landscape of NSCLC management, the 2022 Targeted Therapies Forum presents a dedicated breakout session on ‘First Line Therapy for BRAF+ and NTRK+ NSCLC’. Join Dr. Seetharamu and Dagogo-Jack as they elucidate the strategies, challenges, and groundbreaking advancements surrounding BRAF and NTRK targeted treatments for non-small cell lung cancer. A huge shoutout to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological innovations by visiting http://cancerGRACE.org/. Join our vibrant community of professionals and enthusiasts, and partake in enriching discussions at https://cancergrace.org/forum.
In a specialized breakout session from the 2022 Targeted Therapies Forum, Dr. Nagashree Seetharamu delves deep into the world of NTRK+ NSCLC treatment. Learn the intricacies of two promising medications, Larotrectinib & Entrectinib, that are setting new benchmarks in the realm of non-small cell lung cancer therapies. Special thanks to our committed sponsors for their continual support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For cutting-edge insights and groundbreaking discoveries in oncology, ensure to visit http://cancerGRACE.org/. Engage with a community of experts and fellow enthusiasts by joining the conversation at https://cancergrace.org/forum.
Dive into the intricacies of NTRK mutations in non-small cell lung cancer with Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum. Uncover why testing for NTRK mutations is pivotal, and explore the various methodologies employed in the process. Our heartfelt gratitude to our esteemed sponsors for championing this cause: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncology research and breakthroughs. Visit http://cancerGRACE.org/. Engage with experts and a community driven by the same passion. Join the conversation at https://cancergrace.org/forum.
Ever wondered about the nuances of NTRK mutations in oncology? Join Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum as she delves deep into the specifics of NTRK mutations and their role in cancer. A special thanks to our dedicated sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper dive into the latest in cancer research and treatments, visit http://cancerGRACE.org/. Connect with experts and a community dedicated to understanding and battling cancer. Engage with us at https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Ibiayi Dagogo-Jack examines whether BRAF/MEK combination treatment works in all BRAF+ mutations. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo and Jeffrey Thompson answer a question regarding hormonal therapy and cancer treatment. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss Crizotinib as adjuvant treatment for ROS1+ disease, and the importance of genetic testing overall. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss when to use targeted therapy in HER2+ disease, and possible upcoming trials. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo answers a question regarding developing a second mutation with ROS1. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson examines results from several trials for HER2+ NSCLC treatments. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson looks at HER2+ NSCLC closely, including treatment options. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson discusses the evolving field of NSCLC treatment, and the importance of targeted therapies. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo examines the use of chemotherapy and immunotherapy in ROS1+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dive into the ever-evolving world of ROS1+ treatment options with Dr. Alejandro Calvo. In this specialized session from the 2022 Targeted Therapies Forum, learn about the potential benefits of Lorlatinib and Repotrectinib for patients grappling with ROS1+ disease. Our gratitude goes out to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Craving more insights on cutting-edge cancer treatments? Explore http://cancerGRACE.org/. Engage with our passionate community and renowned experts at https://cancergrace.org/forum.
Unravel the complexities of ROS1+ NSCLC treatment with Dr. Alejandro Calvo. In this illuminating segment from the 2022 Targeted Therapies Forum, delve into the details of Crizotinib and Entrectinib — two promising medications championed for ROS1+ NSCLC care. We’d like to express our heartfelt gratitude to our incredible sponsors for their continued support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Eager to delve deeper into the realm of innovative cancer treatments? Discover more at http://cancerGRACE.org/. Engage with our dynamic community and leading experts at https://cancergrace.org/forum.
Dive deep into ROS1+ NSCLC with Dr. Alejandro Calvo. In this captivating segment from the 2022 Targeted Therapies Forum, gain a comprehensive understanding of ROS1 mutations, the diagnostic tests employed, and the cutting-edge treatment options available. Special thanks to our esteemed sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To journey further into the world of advanced cancer therapies and join in the discussion with experts and peers, explore more at http://cancerGRACE.org/ and visit our forum at https://cancergrace.org/forum.
Experience the transformation of lung cancer treatment over the years with Dr. Alejandro Calvo. This 2022 Targeted Therapies Forum session provides an insightful examination into how first-line treatments for NSCLC have evolved, adapting to new discoveries and technological advancements. We express our gratitude to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their support is pivotal in continuing this essential dialogue. To delve deeper into the vast world of cancer research and treatments, and to connect with a community dedicated to understanding and combating this disease, visit http://cancerGRACE.org/ and engage at https://cancergrace.org/forum.
Considering traveling for a clinical trial? Before you pack your bags, get expert insights from Dr. Angel Qin in this 2022 Targeted Therapies Forum. Dr. Qin delves into the many factors that potential participants should weigh when considering travel for a trial, helping patients and families make informed decisions about their treatment journey. Special thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in our mission to inform and connect the cancer community. To delve deeper into the intricate world of cancer treatments, research, and patient experiences, visit http://cancerGRACE.org/. Join our community…
Disease progression in cancer treatments can be complex, especially when it comes to commonly used medications like Lorlatinib or Osimertinib. Dive deep into this crucial topic with Dr. Millie Das and Angel Qin in the 2022 Targeted Therapies Forum. Unravel the intricacies of how these medications work, why there might be progression, and what steps can be taken next. We are deeply thankful to our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their commitment to fostering patient education and advocacy. To further your knowledge on the evolving landscape of cancer treatments and therapies, head over to http://cancerGRACE.org/.…
Uncommon mutations present unique challenges in cancer treatments, especially when it comes to EGFR mutations. In the 2022 Targeted Therapies Forum, Dr. Angel Qin and Millie Das provide a comprehensive breakdown of the treatment protocols for these mutations and delve into the intricate issues surrounding insurance complications for mutation testing. Our gratitude extends to our supportive sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their dedication to the betterment of cancer research and patient care. Stay informed and ahead in the evolving landscape of cancer treatments. Explore more insights at http://cancerGRACE.org/. For an interactive experience, join our community…
As cancer treatment progresses, managing side effects becomes paramount. In this insightful session from the 2022 Targeted Therapies Forum, Drs. Millie Das and Angel Qin share expert recommendations on treating mouth sores, a common yet distressing side effect. Additionally, for those looking to mitigate other side effects, they guide viewers on finding relevant clinical trials that offer promising solutions. A big thank you to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for championing the cause of cancer research and patient well-being. Empower yourself with more knowledge and stay updated with the latest in cancer care. Dive…
Dive deep into the world of EGFR TKIs with Dr. Millie Das and Angel Qin in this enlightening session from the 2022 Targeted Therapies Forum. Explore the efficacy of EGFR TKIs, their potential combinations, and their strategic use post-chemotherapy to optimize treatment outcomes in cancer patients. A heartfelt acknowledgment to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in advancing cancer research and patient care. Equip yourself with the latest advancements in cancer therapy. Explore further at http://cancerGRACE.org/. Join our dedicated community and be part of the conversation at https://cancergrace.org/forum.
Explore the frontier of ALK+ NSCLC treatments in this in-depth session from the 2022 Targeted Therapies Forum, led by the esteemed Dr. Millie Das. As ALK+ NSCLC continues to be a central topic in oncological research, this video sheds light on the most promising emerging therapies and their potential implications for patient care. Special thanks to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their continued support in pushing the boundaries of cancer treatment and research. Stay updated with the latest breakthroughs in cancer treatment and research. Dive deeper at http://cancerGRACE.org/. Engage with a community of…
Addressing the challenges of ALK TKIs, this insightful session from the 2022 Targeted Therapies Forum is brought to you by the distinguished Dr. Millie Das. In the vast landscape of cancer treatments, ALK TKIs have shown significant promise, but like all therapies, they come with their considerations. Huge appreciation to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their commitment drives progress in the ever-evolving realm of oncology. For a deeper dive into the advancements and discussions in cancer treatment, explore http://cancerGRACE.org/. Engage and share with our expert community at https://cancergrace.org/forum.
Dive into the dynamic world of ALK+ NSCLC treatment with Dr. Millie Das, a prominent figure in oncology, as she unveils the journey and rigorous processes behind the approval of current medications. Hosted by the 2022 Targeted Therapies Forum, this session offers a rich blend of insight and knowledge. Heartfelt thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, whose dedication fuels the advancement in cancer care. Stay updated with the latest in cancer treatments and join our growing community. Discover more at http://cancerGRACE.org/. For engaging discussions and shared experiences, head over to https://cancergrace.org/forum.
Understanding ALK+ NSCLC? Dive into this illuminating session as Dr. Millie Das, a renowned oncologist, breaks down what ‘ALK+’ signifies in the context of lung cancer. This special segment is part of the 2022 Targeted Therapies Forum, connecting you with the latest insights in oncology. Our deepest appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Your support continually pushes the boundaries of cancer research and patient care. Stay abreast of the evolving world of cancer treatments. Learn more and enrich your knowledge at http://cancerGRACE.org/. Engage, ask, and converse with our global community at https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses next steps if Osimertinib stops working. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin examines the various TKIs for EGFR+ NSCLC, and their side effects. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video Dr. Angel Qin explains what EGFR+ lung cancer is. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Drs. Desai, Kim, and Florez discuss whether side effects of TKIs decrease over time. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video, Drs. Preeshagul, Florez, Hirsch, and Kim discuss what it means when a patient with stage 4 ALK+ disease develops L1196M while taking Loratinib. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video, Dr. Chul Kim discusses how to treat the rare percentage of patients with EGFR+ disease who develop pneumonitis and can no longer take Erlotinib. We thank our sponsors for this year’s support!#genentech Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Dr. Narjust Florez addresses the complicated question of progression for a patient with stage 4 ALK+ disease who developed new lesions after reducing Alectinib. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Dr. Aakash Desai presents Dr. Chul Kim response to a patient who is concerned their nodularities on Alectinib are pneumonitis. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Dr. Isabel Preeshagul presents Dr. Fred R. Hirsch response to a patient who switched to Osimertinib from Erlotinib and saw disease progression. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Drs. Isabel Preeshagul and Narjust Florez, discuss treatment of a patient diagnosed with EGFR mutated NSCLC that metastasized to the brain. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Drs. Aakash Desai and Narjust Florez, discuss how she approaches oligoprogression with mutations other than EGFR. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: In this video Drs. Isabel Preeshagul and Chul Kim, discuss if side effect symptoms mean a patient is responding better to treatment? We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: Dr. Aakash Desai, Hematology/Oncology Fellow, Mayo Clinic, Rochester, MN, and Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine; Associate Director, Biomarker Discovery for TCI, Questions and answers morning session. In this video, Dr. Fred Hirsch briefly examines if DNA or RNA is better for NGS. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022: Dr. Aakash Desai, Hematology/Oncology Fellow, Mayo Clinic, Rochester, MN, and Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine; Associate Director, Biomarker Discovery for TCI, Questions and answers morning session. In this video, Dr. Fred Hirsch discusses which patients should receive NGS. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss adding immunotherapy to chemotherapy for patients with mesothelioma.…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo discuss whether adding a PARP inhibitor is beneficial to…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo examine treatment options for patients with EGFR+ disease, who…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo look at data on Sunvozertinib’s use against EGFR Exon…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO. Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials. In this video, Drs. West, Lovly, and Addeo look at tumor treating fields for lung cancer, and…
Colorectal cancer is a growing concern, and its incidence among younger individuals, known as young-onset colorectal cancer (yoCRC), has been on the rise. This alarming trend has prompted researchers to delve deeper into the factors contributing to this phenomenon. One study, titled “Metabolomic Differences in Young-Onset versus Average-Onset Colorectal Adenocarcinoma,” focuses on identifying metabolomic disparities between yoCRC and average-onset CRC (aoCRC) to shed light on the underlying causes and potential exposure risks associated with yoCRC. Metabolomics, a cutting-edge field of study, examines the unique chemical fingerprints present in cellular metabolism. By analyzing metabolites in plasma, this study aims to uncover…
KEY TAKEAWAYS Bispecific antibodies, such as talquetamab, represent a transformative shift in cancer treatment, offering the potential to target two antigens simultaneously and more effectively involve the immune system in the fight against cancer. Talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, has shown promising results in the MonumenTAL-1 trial, even among heavily pretreated patients with relapsed/refractory multiple myeloma. Ribociclib, a CDK4/6 inhibitor, is a groundbreaking drug for the treatment of breast cancer. It works differently from bispecific antibodies, but its advent represents another leap forward in cancer therapeutics. Combination therapies, involving drugs like ribociclib and bispecific antibodies, could be a powerful…